International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
08. März 2023 08:00 ET
|
Esperion Therapeutics, Inc.
– International Lipid Expert Group Recommends Earlier Utilization of Bempedoic Acid in Both Secondary Prevention Patients As Well As in Patients with Partial or Complete Statin Intolerance – ...
Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
06. April 2021 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
04. Juni 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with...
Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
20. April 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– Esperion to Receive $60 Million Upfront Payment – – Up to $510 Million in Total Milestones – – Substantial Tiered Royalties – – Combines Esperion’s Expertise in Lipid Management with...
Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)
28. März 2020 09:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2...
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)
23. März 2020 07:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2...
Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
18. März 2020 07:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of...
Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
27. Februar 2020 07:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided lipid management franchise updates and financial results for the fourth quarter and year ended December 31,...
Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
26. Februar 2020 17:30 ET
|
Esperion Therapeutics, Inc.
- NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins -- First Non-Statin, LDL-Cholesterol Lowering Combination Medicine Ever Approved -- Esperion’s...
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
21. Februar 2020 16:38 ET
|
Esperion Therapeutics, Inc.
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients –– NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism...